1 / 5

Voso et al, Supplementary Figure 1

Oligonucleotide sequences and PCR conditions used for sequencing. Voso et al, Supplementary Figure 1. Exemplary sequencing reactions for all genes studied. Voso et al, Supplementary Figure 2. Time to Leukemic evolution. SRSF2-mutated. SRSF2-wild type. Probability (%). p=0.04.

chaim-hunter
Télécharger la présentation

Voso et al, Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oligonucleotide sequences and PCR conditions used for sequencing Voso et al, Supplementary Figure 1

  2. Exemplary sequencing reactions for all genes studied Voso et al, Supplementary Figure 2

  3. Time to Leukemic evolution SRSF2-mutated SRSF2-wild type Probability (%) p=0.04 Months from MPN diagnosis Voso et al, Supplementary Figure 3

  4. Characteristics of patients with leukemias secondary to chronic myeloproliferative neoplasms *Of 5 patients with a complex karyotype, 2 had 11q23 abnormalities and 3 had a chromosome 5 and/or 7 deletion Voso et al, Supplementary Table 1

  5. Prevalence of mutations in patients with leukemias Secondary to chronic myeloproliferative neoplasms * One patient with a previous PV had synchronous IDH2 R140Q and DNMT3A R882H mutations ** p=0.025 Voso et al, Supplementary Table 2

More Related